Monoclonal antibodies in the management of solid tumors

Current Topics in Medicinal Chemistry

Volumn 6, Issue 16, 2006, Pages 1687-1705

  Kalofonos, Haralambos P ^a   Grivas, Petros D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Antibody; Bevacizumab; Cetuximab; EGFR; HER2 neu; Immunotherapy; Trastuzumab; VEGF

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CHIMERIC ANTIBODY; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GEMCITABINE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PSEUDOMONAS EXOTOXIN; RADIOISOTOPE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ASTHENIA; BLEEDING; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONJUNCTIVITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGLOBULIN VARIABLE REGION; ISOTOPE LABELING; LIVER TOXICITY; LUNG HEMORRHAGE; MUCOSAL BLEEDING; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PATIENT SELECTION; PROTEINURIA; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; STOMATITIS; THROMBOSIS; TUMOR BLEEDING;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNIZATION, PASSIVE; NEOPLASMS;

EID: 33748302886     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778194208     Document Type: Review

References (159)

1. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
2. Nadler, L.M., Stashenco, P., Hardy, R., Schlossman, S.F. A monoclonal antibody defining a lymphoma-associated antigen in man. J. Immunol. 1980, 125(2), 570-577.
3. Miller, R.A., Maloney, D.G., McKillop, J., Levy, R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981, 58, 78-86.
4. Sears, H.F., Atkinson, B., Mattis, J., Ernst, C., Herlyn, D., Steplewski, Z., Hayry, P., Koprowski, H. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982, 1(8275), 762-765.
5. Rony, Abou-Jawed., Toni, Choueiri., Carlos, Alemani., Tarek, Mekheil. An overview of targeted treatments in cancer. Clin. Therapeut. 2003, 25(8), 2121-2137.
6. Green, M.C., Murray, J.L. and Hortobagyi, G.N. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev. 2000, 26, 269-286.
7. Sliwkoski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M., Fox, J.A. Non clinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin. Oncol. 1999, 26 (suppl 12), 60-70.
8. Kreitman, R.J. Immunotoxins in cancer therapy. Curr. Op. Immunol. 1999, 11, 570-578.
9. Siegall, C.B., Chace, D., Mixan, B., Garrigues, U., Wan, H., Paul, L., Wolff, E., Hellstrom, I., Hellstrom, K.E. In vitro and in vivo characterization of BR96 sFv-PE40. J. immunol. 1994, 152 (5), 2377-2384.
10. Zangemeister-Wittke, U., Collinson, A.R., Fisch, I., Jones, R.M., Waibel, R., Lenham, H.P., Stahel, R.A. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small cell lung cancer. Int. J. Cancer 1993, 54, 1028-1035.
11. Williams, L.E., Liu, A., Wu, A.M., Odom-Maryon, T., Chai, A., Raubitschek, A.A., Wong, J.Y. Figures of merit (FOMs) for imaging and therapy using MAbs . Med. Phys. 1995, 22, 2025-2027.
12. Margaret, von Mehren., Gregory, P. Adams, and Louis, M. Weiner. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 2003, 54, 343-369.
13. Garnett, M.C., Embleton, M.J., Jacobs, E., Baldwin, R.W. Studies in the mechanism of action of an antibody targeted drug-carrier conjugate. Anticancer Drug Des. 1985, 1, 3-12.
14. Bagswawe, K.D., Sharma, S.K., Burke, P.J., Melton, R.G., Knox, R.J. Developments with targeted enzymes in cancer therapy. Curr. Op. Immunol. 1999, 11, 579-583.
15. Steplewski, Z., Lubeck, M., Koprowski, H. Human macrophages armed with murine immumoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983, 221, 865-868.
16. Hellstrom, I., Beaumier, P., Hellstrom, K.E. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc. Natl. Acad. Sci. USA 1986, 83, 7060-7062.
17. Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., Lindhofer, H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 1999, 163, 1246-1252.
18. Suzanne, A Eccles. MAbs targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res. 2001, 3, 86-90.
19. Clynes, R.A, Towers, T.L., Presta, L.G., Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6, 443-446.
20. Anasetti, C., Martin, P., Morishita, Y., Badger, C.C., Bernstein, I.D., Hansen, J.A. Human large granular lymphocytes express high affinity receptors for murine MAbs of the IgG3 subclass. J. Immunol. 1987, 138, 2979-2981.
21. Ortaldo, J.R., Woodhouse, C., Morgan, A.C., Herberman, R.B., Cheresh, D.A., Reisfeld, R. Analysis of effector cells in human antibody dependent cellular cytotoxicity with murine MAbs. J. Immunol. 1987, 138 (10), 3566-3572.
22. Khazaeli, M.B., Conry, R., LoBuglio, A. Human immune response to MAbs. J. Immunol. 1994, 15, 42-52.
23. Sakahara, H., Saga, T., Onodera, H., Yao, Z., Nakamoto, Y., Zhang, M., Sato, N., Nakada, H., Yamashina, I., Endo, K., Konishi, J. Anti-murine antibody response to mouse MAbs in cancer patients. Jpn. J. Can. Res. 1997, 88, 895-899.
24. Peterson, J., Couto, J., Taylor, M., Ceriani, R. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res. 1995, 55, 5847s-5851s.
25. Kalofonos, H., Rowlinson, G and Epenetos, A.A. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res. 1990, 50, 159-163.
26. Saleh, M.N., Khazaeli, M.B., Wheeler, R.H., Dropcho, E., Liu, T., Urist, M., Miller, D.M., Lawson, S., Dixon, P., Rusell, C.H. Phase I trial of the murine monoclonal anti GD-2 antibody 14G2a in metastatic melanoma. Cancer Res. 1992, 52, 35294-35300.
27. Badger, C., Anasetti, C., Davis, J., Bernstein, I. Treatment of malignancy with unmodified antibody. Pathol. Immunopathol. Res. 1987, 6, 419-434.
28. Holland, G., Zlotnik, A. Interleukin-10 and cancer. Cancer Invest. 1993, 11, 751-758.
29. Lee, J., Fenton, B.M., Koch, C.J., Frelinger, J.G., Lord, E.M. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 1998, 58 (7), 1478-1485.
30. Kalofonos, H., Rusckowski, M., Siebecker, D.A., Sivolapenko, G.B., Snook, D., Lavender, J.P., Epenetos, A.A. and Hnatowich, D.J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin conjugated antibodies. J. Nucl. Med. 1990, 31, 1791-1796.
31. Rodwell, J.D. Engineering MAbs. Nature 1989, 342, 99-100.
32. Buist, M.R., Kenemans, P., van Kamp, G., Haisma, H. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single IV infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol. Immunother. 1995, 40, 24-30.
33. Van, Zaanen, H., Lokhorsti, H., Aarden, L., van Oers, M. Chimeric anti-interleukin 6 MAbs in the treatment of an advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 1998, 102, 783-790.
34. Goodman, G., Hellstrom, I., Yelton, D.E., Murray, U., O'Hara, S., Meaker, E., Zeigler, L., Palazollo, P., Nicaise, C., Usakewicz, J. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon and breast cancer. Cancer Immunol. Immunother. 1993, 36, 267-273.
35. Riechmann, L., Clark, M., Waldmann, H., Winter, G. Reshaping human antibodies for therapy. Nature 1988, 332, 323-327.
36. Sivolapenko, G.B., Douli, V., Pectasides, D., Skarlos, D., Sirmalis, G., Hussain, R., Cook, J., Courtenay-Luck, N.S., Merkouri, E., Konstantinides, K. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumor antibody. Lancet 1995, 346, 1662-1266.
37. Le Gall, F., Kipriyanof, S.M., Moldenhauer, G., Little, M. Di, tri-and tetrameric single chain Fv antibody fragments against human CD19: effects of valency on cell binding. FEBS Lett. 1999, 453, 164-168.
38. Begent, R.H., Verhaar, M.J., Chester, K.A., Casey, J.L., Green, A.J., Napier, M.P., Hope-Stone, L.D., Cushen, N., Keep, P.A., Johnson, C.J., Hawkins, R.E., Hilson, A.J., Robson, L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 1996, 2, 979-984.
39. Holliger, P., Prospero, T., Winter, G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993, 90, 6444-6448.
40. Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L.E., Wong, J.Y., Shively, J.E., Wu, A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996, 56, 3055-3061.
41. Velu, T.J., Beguinot, L., Vass, W.C., Willingham, M.C., Merlino, G.T., Pastan, I., Lowy, D.R. Epidermal-growth-factor-dependent transfor-mation by a human EGF receptor proto oncogene. Science 1987, 238, 1408-1410.
42. Di Marco, E., Pierce, J.H., Fleming, T.P., Kraus, M.H., Molloy, C.J., Aaronson, S.A., Di Fiore, P.P. Autocrine interaction between TGF-a and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1989, 4, 831-838.
43. Uegaki, K., Nio, Y., Inoue, Y., Minari, Y., Sato, Y., Song, M.M., Dong, M., Tamura, K. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997, 17, 3841-3847.
44. Voldborg, B.R., Damstrup, L., Spang-Thomsen, M., Poulsen, H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 1997, 8, 1997-1206.
45. Wells, A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer. Res. 2000, 78, 31-101.
46. Verbeek, B.S., Adriaansen-Slot, S.S., Vroom, T.M., Beckers, T., Rijksen, G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 1998, 425, 145-150.
47. Riedel, F., Gotte, K., Li, M., Hormann, K., Grandis, J.R. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int. J. Oncol. 2002, 21, 11-16.
48. Eccles, S.A. Cell biology of lymphatics metastasis. The potential role of c-erbB oncogene signaling. Recent Results Cancer Res. 2000, 157, 41-54.
49. Nicholson, R.I., Gee, J.M.W., Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001, 37, S9-S15.
50. Kalofonos, H., Pawlikowska, T.R., Hemingway, A., Courtenay-Luck, N., Dhokia, B., Snook, D., Sivolapenko, G.B., Hooker, G., McKenzie, C.G., Lavender, P.J., Thomas, D.G.T. and Epenetos, A.A. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled MAbs against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. 1989, 30 (10), 1636-1645.
51. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 2001, 8, 3-9.
52. Mandal, M., Adam, L., Mendelsohn, J., Kumar, R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998, 17, 999-1007.
53. Liu, B., Fang, M., Schmidt, M., Lu, Y., Mendelsohn, J., Fan, Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor MAbs in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer 2000, 82, 1991-1999.
54. Ferreira, C.G., Epping, M., Kruyt, F.A., Giaccone, G. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002, 8, 2024-2034.
55. Bandyopadhyay, D., Mandal, M., Adam, L., Mendelsohn, J., Kumar, R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem. 1998, 273, 1568-1573.
56. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A.R., Tortora, G. Anti-tumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 1999, 5, 909-916.
57. Inoue, K., Slaton, J.W., Perrotte, P., Davis, D.W., Bruns, C.J., Hicklin, D.J., McConkey, D.J., Sweeney, P., Radinsky, R., Dinney, C.P. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 2000, 6, 4874-4884.
58. Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B., Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinases down regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy for solid tumors. Am. J. Pathol. 1997, 151, 1523-1530.
59. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B.Y., Hicklin, D.J., Radinsky, R., Dinney, C.P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 1999, 5, 257-265.
60. Bruns, C.J., Harbison, M.T., Davis, D.W., Portera, C.A., Tsan, R., McConkey, D.J., Evans, D.B., Abbruzzese, J.L., Hicklin, D.J., Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antioangiogenic mechanisms. Clin. Cancer Res. 2000, 6, 1936-1948.
61. Huang, S.M., Harari, P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 1999, 17, 259-269.
62. Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A., Mueller, B.M. Therapeutic potential of chimeric and murine anti-epidermal growth factor receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 1993, 37, 343-349.
63. Prewett, M., Rockwell, P., Rose, C., Zulkys, K., Goldstein, N. Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid cell carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor. Molec. Cell Different. 1996, 4, 167-186.
64. Saleh, M.N., Raisch, K.P., Stackhouse, M.A., Grizzle, W.E., Bonner, J.A., Mayo, M.S., Kim, H.G., Meredith, R.F., Wheeler, R.H., Buchsbaum, D.J. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Mother. Radipharm. 1999, 14, 451-463.
65. Bonner, J.A., Raisch, K.P., Trummell, H.Q., Robert, F., Meredith, R.F., Spencer, S.A., Buchsbaum, D.J., Saleh, M.N., Stackhouse, M.A., LoBuglio, A.F., Peters, G.E., Caroll, W.R., Waksal, H.W. Enhanced apoptosis with combination C225/radiatiori treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 2000, 18, 47S-53S.
66. Huang, S.M., Bock, J.M., Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 1935-1940.
67. Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A.R., Ciardello, F. Anti-tumor activity of combined treatment of human cancer cells with ionizing radiation and anti -epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin. Cancer Res. 2000, 6, 4343-4350.
68. Prewett, M.C., Hooper, A.T., Bassi, R., Ellis, L.M., Waksal, H.W., Hicklin, D.J. Enhanced anti tumor activity of anti -epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 2002, 8, 994-1003.
69. Prewett, M.C., Hooper, A.T., Bassi, R. Enhanced anti-tumor activity of anti -epidermal growth factor receptor monoclonal antibody cetuximab (IMC-C225) in combination with irinotecan (CPT-11), 5-FU, and leucovorin against human colorectal carcinoma xenografts. Eur. J. Cancer 2002, 8 (Suppl 7).
70. Zolfaghari, A., Djakiew, D. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function. Prostate 1996, 28, 232-238.
71. Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T., Koff, A., Mendelsohn, J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12, 1397-1403.
72. Baselga, J., Pfister, D., Cooper, M.R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunett, K., Falcey, J., Anderson, V., Waksal, H., Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18, 904-914.
73. Robert, F., Ezekiel, M.P., Spencer, S.A., Meredith, R.F., Bonner, J.A., Khazaeli, M.B., Saleh, M.N., Carey, D., Lo Buglio, A.F., Wheeler, R.H., Cooper, M.R., Waksal, H.W. Phase I studies of anti epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 3234-3243.
74. Baselga, J., Mendelsohn, J. Receptor blockade with MAbs as anti-cancer therapy. Pharmacol. Ther. 1994, 64, 127-154.
75. Baselga, J., Trigo, J.M., Bourchis, J., Tortochaux, J., Cortes-Funes, H., Hitt, R., Gascon, P., Amellal, N., Harstrick, A., Eckardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23(24): 5440-5442.
76. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinitecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351(4), 337-345.
77. Karamouzis, M.V., Likaki-Karatza, E., Ravazoula, P., Badra, F.A., Koukouras, D., Tzorakoleftherakis, E., Papavassiliou, A.G., Kalofonos, H.P. Non-palpable breast carcinomas: correlation of mammogra-phically detected malignant-appearing microcalcifications and molecular prognostic factors. Int. J. Cancer 2002, 102(1), 86-90.
78. Ravdin, P.V., Channess, G.C. The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers. Gene 1995, 159, 19-27.
79. Seshadri, R., Firgaira, F.A., Horsfall, D.J., McCaul, K., Setlur, V., Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol. 1993, 11, 1936-1942.
80. Piccart, M.J., Di Leo, A., Hamilton, A. Her2: a predictive factor ready to use in the daily management of breast cancer patient? Eur. J. Cancer 2002, 36, 1755-1761.
81. Arteaga, C. Trastuzumab, an appropriate first-line single-agent therapy for HER2 overxpressing breast cancer. Breast Cancer Res. 2003, 5, 96-100.
82. Harries, M., Smith, I. The development and clinical use of trastuzumab. Endocr. Relat. Cancer. 2002, 9, 75-85.
83. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seisman, A.D., Hudis, C.A., Moore, J., Rosen, P.P., Twadell, T., Henderson, I.C., Norton. L. Phase II study of weekly intravenous recombinant humanized anti-p185 (HER-2) monoclonal antibody in patients with HER-2-neu overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14, 737-744.
84. Pegram, M., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A., Slamon, D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185 (HER-2) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998, 16, 2659-2671.
85. Cobleigh, M., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., Slamon, D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17, 2639-2648.
86. Vogel, C., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., Shak, S., Stewart, S.J., Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
87. Slamon, D.J., Leyland-Jones, B., Shak, S, Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
88. Michel, Marty., Francesco, Cognetti., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Anton, A., Lluch, A., Kennedy, J., O'Byrne, K., Conte, P., Green, M., Ward, C., Mayne, K., Extra, J.M. Randomized phase II trial of the efficacy and safety of Trastuzumab combined with Docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group. J. Clin. Oncol. 2005, 23 (19), 4265-4274.
89. Pegram, M., Konecny, G.E., O'Callaghan, C., Beryt, M., Pietras, R., Slamon, D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 2004, 96, 739-749.
90. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., Slamon, D. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18, 2241-2251.
91. Burstein, H.J., Kuter, I., Campos, S.M., Gelman, R.S., Tribou, L., Parker, L.M., Manola, J., Younger, J., Matulonis, U., Bunell, C.A., Partridge, A.H., Richardson, P.G., Clarke, K., Shulman, L.N., Winer, E.P. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2001, 19, 2722-2730.
92. Jahanzeb, M., Mortimer, J.E., Yunus, F., Irwin, D.H., Speyer, J., Koletsky, A.J., Klein, P., Sabir, T., Kronish, L. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002, 7, 410-417.
93. Esteva, F.J., Valero, V., Booser, D., Guerra, L.T., Murray, J.L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H.A., Sneige, N., Smith, T.L., Hortobagyi, G.N. Phase trial of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20 (7), 1800-1808.
94. Untch, M., Eidtmann, H., du Bois, A., Meerpohl, H.G., Thomssen, C.h., Ebert, A., Harbeck, N., Jackisch, C., Heilman, V., Emons, G., Wallwiener, D., Wiese, W., Blohmer, J.U., Hoffken, K., Kuhn, W., Reichardt, P., Muscholl, M., Pauschinger, M., Langer, B., Luck, H.J. Cardiac safety of Herceptin in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer:results of a phase I trial. Eur. J. Cancer 2004, 40, 988-997.
95. O'Shaughnessy, J.A., Vukelja, S., Marsland, T., Kimmel, G., Ratnam, S., Pippen, J.E. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer 2004, 5(2), 142-147.
96. Miller, K.D., Sisk, J., Ansari, R., Gize, G., Nattam, S., Pennington, K., Monaco, F., Sledge, G.W. Jr. Gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer. Oncology 2001, 15 (2 suppl 3), 38-40.
97. Bangemann, N., Kuhle, A., Ebert, A., Buhler, H., Schaller, G. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2 overexpressing metastatic breast cancer (MBC). Ann. Oncol. 2000, 11 (suppl 4), 143.
98. Pegram, M.D., Pienkowski, T., Northfelt, D.W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., Riva, A., Blitz, S., Press, M.F., Reese, D., Lindsay, M-A., Slamon, D.J. Results of two open-label, multicenter phase I studies of docetaxel, platinum salts and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer Inst. 2004, 96, 759-769.
99. Pietras, R.J., Poen, J.C., Gallardo, D., Wongvipat, P.N., Lee, H.J., Slamon, D.J. Monoclonal antibody to HER2/neu receptor modulates repair of radiation induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999, 59, 1347-1355.
100. Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rung, H.M., Bauerfeind, I., Felber, M., Wang, H.J., Beryt, M., Seshdri, R., Hepp, H., Slamon, D.J. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive breast cancer. J. Natl. Cancer Inst. 2003, 95, 142-153.
101. Wright, C., Nicholson, S., Angus, B., Sainsbury, J.R., Famdon, J., Cairns, J., Harris, A.L., Horne, C.H. Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 1992, 65, 118-121.
102. Elledge, R.M., Green, S., Ciocca, D., Pugh, R., Allred, D.C., Clark, G.M., Hill, J., Ravdin, P., O'Sullivan, J., Martino, S., Osborne, C.K. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin. Cancer Res. 1998, 4, 7-12.
103. Carlomagno, C., Perrone, F., Gallo, C., De Laurentis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A.R., De Placido, S. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymph node metastasis. J. Clin. Oncol. 1996, 14, 2702-2708.
104. Lipton, A., Ali, S.M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L., Harvey, H.A., Brady, C., Nalin, C.M., Dugan, M., Carney, W., Allard, J. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 2002, 20, 1467-1472.
105. Mouridsen, H., Gershanovich, M, Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H.P., Janicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P.P., Salminem, E., Snyder, R., Lassus, M., Verbeek, J.A., Staffler, B., Chaudri-Ross, H.A., Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001, 19, 2596-2606.
106. Ellis, M. Overcoming endocrine resistance by signal transduction inhibition. Oncologist 2004, 9, 20-26.
107. Shou, J. Mechanisms of tamoxifen resistance: increased estrogen-receptor HER2/neu cross talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96, 926-935.
108. Normanno, N., Campiglio, M., De, L.A., Somenzi, G., Maiello, M., Ciardello, F., Gianni, L., Salomon, D.S., Menard, S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab on human breast cancer cell growth. Ann. Oncol. 2002, 13, 65-72.
109. Nahta, R. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64, 2343-2346.
110. Colombo, M.P., Trinchieri, G. Interleukin -12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13, 155-168.
111. Robertson, M.J., Cameron, C., Atkins, M.B., Gordon, M.S., Lotze, M.T., Sherman, M.L., Ritz, J. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 1999, 5, 9-16.
112. Repka, T., Chiorean, E.G., Gay, J., Herwig, K.E., Kohl, V.K., Yee, D., Miller, J.S. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin. Cancer Res. 2003, 9, 2440-2446.
113. Konecny, G.E., Meng, Y.G., Untch, M., Wang, H-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J-M., Gutierrez, J., Hong, K., Beryt, M., Hepp, H., Slamon, D.J., Pegram, M.D. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. 2004, 10, 1706-1716.
114. Pegram, M.D., Yeon, C., Ku, N.C., Gaudreault, J., Slamon, D.J. Phase I combined biological therapy of breast cancer using two humanized MAbs directed against HER2 proto oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat. 2004, 88, 124-125.
115. O'Shaoughnessy, J.A. Recent advances in the treatment of metastatic breast cancer. Clin. Oncol. Updates 2002, 5, 1-17.
116. Christina, H. Yeon, and Mark, D. Pegram. Anti-erbB2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs, 2005, 23, 391-409.
117. Trastuzumab trials steal show at ASCO Meeting, News 870-871. J. Nat. Cancer Instit. 2005, 97 (12).
118. Cook-Bruns, N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001, 61 (suppl 2), 58-66.
119. Keefe, D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95, 1592-1600.
120. Burstein, J. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2-overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. 2003, 21, 46-53.
121. Bookman, M.A., Darcy, K.M., Clark-Pearson, D., Boothby, R.A., Horowitz, I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritonel carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003, 21(2), 283-90.
122. Zinner, R.G., Glisson, B.S., Fossella, F.V., Pisters, K.M., Kies, M.S., Lee, P.M., Massarelli, E., Sabloff, B., Fritsche, H.A. Jr, Ro, J.Y., Ordonez, N.G., Tran, H.T., Yang, Y., Smith, T.L., Mass, R.D., Herbst, R.S. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2 overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004, 44(1), 99-110.
123. Weidner, N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. Pathol. 1998, 184, 119-122.
124. Darland, D.C., D'Amore, P.A. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 1999, 103, 157-158.
125. Ferrara, N., Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997, 18, 4-25.
126. Paley, P.J., Goff, B.A., Gown, A.M., Greer, B.E., Sage, E.H. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80, 98-106.
127. Volm, M., Koomagi, R., Mattern, J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 1997, 74, 64-68.
128. Maeda, K., Chung, Y.S., Ogawa, Y., Takatsuka, S., Kang, S.M., Ogawa, M., Sawada, T., Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
129. Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., Matsubara, I., Vinante, O., Bonoldi, E., Boracchi, P., Gatti, C., Suzuki, H., Tominaga, T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997, 89, 139-147.
130. Linderholm, B., Tavelin, B., Grankvist, K., Henriksson, R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 1998, 16, 3121-3128.
131. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R.K., Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94, 715-725.
132. Shweiki, D., Itin, A., Soffer, D., Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
133. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor and its receptors. FASEB J. 1999, 13, 9-22.
134. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Eng. J. Med. 1971, 285, 1182-1186.
135. Margolin, K., Gordon, M.S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D,, Stalter, S., Breed, J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001, 19, 851-856.
136. Borgstrom, P., Gold, D.P., Hillan, K.J., Ferrara, N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999, 19, 4203-4214.
137. Gordon, M., Margolin, K., Talpaz, M., Sledge, G.W. Jr, Holmgren, E., Benjamin, R., Stalter, S., Shak, S., Adelman, D. Phase I safety and pharmacokinetic study of recombinant anti vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843-850.
138. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny,
139. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, F., Ferrara, N, Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350(23), 2335-2342.
140. Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., Findlay, B.P., Pitot, H.C., Alberts, S.R. A randomized controlled trial of fluorouracil plus leukovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004, 22, 23-30
141. Cobleigh, M.A., Langmuir, V.K., Sledge, G.W., Miller, K.D., Haney, L., Novotny, W.F., Remmann, J.D., Vassel, A. A phase I/II dose -escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30 (5,suppl 16), 117-124.
142. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., Dickler, M., Overmover. B.A., Reinmann, J.D., Sing, A.P., Langmuir, V., Rugo, U.S. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
143. Miller, K.D. E2100: a phase III trial of paclitaxel /bevacizumab for metastatic breast cancer. Clin. Breast Cancer 2003, 3, 421-422.
144. Herbst, R.S,, Johnson, D.H., Mininberg, E., Carbone, D.P., Henderson, T., Kim, E.S., Blumenschein, G. Jr, Lee, J.J., Liu, D.D., Truong, M.T., Hong, WK., Tran, H., Tsao, A., Xie, D., Ramies, D.A., Mass, R., Seshagiri, S., Eberhard, D.A. Kelley, S.K., Sandler, A. Phase I/II trial evaluating the anti -vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23(11), 2544-2555.
145. Herbst, R.S., Laskin, J., Mininberg, E. Phase I/II trial evaluating blockade of tumor blood supply and tumor cell proliferation with combined bevacizumab (Avastin) and erlotinib HCL (Tarceva) as targeted cancer therapy in patients with recurrent non small-cell lung cancer. Eur. J. Cancer Suppl. 2004, 1(5), S293.
146. Yang, J.C., Haworth, L., Sherry, R.M., Hvru, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., Rosenberg, S.A. A randomized trial of bevacizumab, an anti vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349(5), 427-434.
147. Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P., Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20(1), 289-296.
148. Hainsworth, J.D., Sosman, J.A., Spigel, D.R., Edwards, D.L., Baughman, C., Greco, A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 2005, 23(31), 7889-7896.
149. Rini, B.I., Halabi, S., Taylor, J., Small, E.J., Schilsky, R.L. Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 2004, 10(8), 2584-2586.
150. Kindler, H.L., Friberg, G., Singh, D.A., Locker, G., Nattam, S., Kozloff, M., Taber, D.A., Karrison, T., Dachman, A., Stadler, W.M., Vokes, E.E. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2005, 23(31): 8033-8040.
151. Yang, X.D., Jia, X.C., Corvalan, J.R.F., Wang, P., Davis, C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol/Hemat. 2001, 38, 17-23.
152. Vanhoefer, U., Tewes, M., Rojo, F., Dirsch, O., Schleucher, N., Rosen, O., Tillner, J., Kovar, A., Braun, A.H., Trarbach, T., Seeber, S., Harstrick, A., Baselga, J. Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 175-184.
153. Lo Km. The role of ADCC effector function in the antitumor activity of anti EGFR antibodies in a mouse xenograft model. Clin. Cancer Res. 2003, 9, A125, 6069S.
154. Tillner, J. Pharmacokinetics (PK) of the novel humanized anti-EGFR Mab EMD72000. Clin. Cancer Res. 2003, 9, A110, 6096S.
155. Trarbach, T., Beyer, T., Schleucher, N. Randomized phase I pharmacodynamic study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with advanced EGFR-expressing tumors: preliminary results of an ongoing study. Clin. Cancer Res. 2003, 9 (A112), 6069S.
156. Zalutski, M.R. Current status of therapy of solid tumors: brain tumor therapy. J. Nucl. Med. 2005, 46 (Suppl 1), 151S-6S.
157. Koppe, M.J., Bleichrodt, R.P., Oyen, W.J., Boerman, O.C. Radioimmunotherapy and colorectal cancer. Br. J. Surg. 2005, 92(3), 264-76.
158. Janessa, J. Laskin and Alan B. Sandler. Epidermal growth factor receptor: a promising target in solid tumors. Cancer Treat. Rev. 2004, 30, 1-17.
159. Fountzilas, G., Christodoulou. C., Tsavlaridis, D., Kalogera-Fountzila, A., Aravantinos, G., Razis, E., Kalofonos, H.P., Papakostas, P., Karina, M., Gogas, H., Skarlos, D. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest. 2004, 22(5), 655-662.